查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1809819

環肽市場：按類型、產品類型、技術、應用和最終用戶 - 全球預測 2025-2030

Cyclic Peptides Market by Type, Product Type, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年環肽市值將達31.6億美元，2025年將成長至33.5億美元，到2030年將達到46.1億美元，複合年成長率為6.52%。

主要市場統計數據
基準年2024年 31.6億美元
預計2025年 33.5億美元
預測年份 2030 46.1億美元
複合年成長率（%） 6.52%

透過跨學科創新、跨產業合作和不斷發展的臨床需求動態，開拓環肽研究的新前沿

環肽已成為一類突破性的治療藥物，其特徵是結構剛性高、穩定性高，且對複雜標靶具有高結合親和性。其獨特的大環骨架賦予其抗蛋白水解能力，使其成為腫瘤、代謝疾病、感染疾病和診斷平台等廣泛應用的理想候選藥物。過去十年，合成方法和生物技術創新的快速發展為以前所未有的精度客製化環肽結構鋪平了道路，加速了先導化合物的鑑定和最佳化。

革命性的技術進步與合作突破重新定義全球環肽研發的軌跡

環肽領域近期的模式轉移是最尖端科技與策略夥伴關係關係的融合，旨在加速藥物的發現與發展。合成平台的自動化，加上增強的純化通訊協定，顯著縮短了生產時間並提高了產量的一致性。同時，機器學習與分子建模的整合改進了靶點參與預測，簡化了先導化合物的最佳化，並減少了後期失敗。

分析2025年美國關稅調整對環肽產業生態系及市場韌性的深遠影響

2025年美國新關稅的實施，為環肽相關人員帶來了複雜的戰略考量。國際採購的原料、特殊試劑和關鍵中間體的進口關稅將上調，這促使企業全面重新評估籌資策略。許多公司正在透過多元化供應商、推行近岸外包以及投資國內製造能力來應對關稅波動的影響。

關鍵市場細分洞察揭示了環肽領域中不同類型、應用和最終用戶的市場動態

仔細觀察市場細分，可以發現跨多個維度的微妙動態。從結構分類的角度來看，天然來源的環肽因其固有的生物活性和已確立的安全性而保持強大的吸引力。這種雙重性推動了研究的均衡發展，天然類似物通常可作為合成最佳化的藍圖。

評估影響美洲、歐洲、中東和非洲以及亞太市場環肽開發和商業化的獨特區域動態

環肽領域的區域趨勢在美洲、歐洲、中東和非洲以及亞太地區存在顯著差異，形成了獨特的開發和商業化路徑。在美洲，對胜肽創新中心的強勁投資和支持性監管政策促進了環肽從實驗室到臨床的快速發展，許多生物技術公司建立了夥伴關係，以促進生產規模的擴大。

介紹主要產業領袖，展示推動策略聯盟發展的創新產品組合，以推動環肽市場的發展

對主要企業的重點研究揭示了推動環肽領域成長的多種策略方法。一些製藥公司正在利用其內部固相合成能力，並建立策略聯盟以獲取新型重組和混合技術，將先進的胜肽平台納入其產品線。這些聯盟通常以共同開發契約、共用製造網路和聯合智慧財產權組合為中心，以加快產品上市速度。

為行業領導者提供策略建議，以利用環肽領域的新機會並鞏固其市場地位

為了抓住環肽市場的新機遇，產業領導者應推行多元化策略，在創新、卓越營運和市場應對力之間取得平衡。首先，投資一個整合固相、混合和重組DNA技術的多元化平台，將使他們能夠快速回應不斷變化的計劃需求，從簡單的類似物到複雜的大環化合物。

方法論嚴謹透明，結合主要研究專家訪談和二手資料綜合，為環肽研究提供強大的見解

本分析採用嚴格的多階段調查方法，旨在確保準確性、相關性和可操作性。二次研究收集了來自同行評審出版物、專利資料庫、監管備案文件和權威行業報告的資訊。這些資訊來源提供了關於技術進步、安全性和應用趨勢的廣泛資訊基礎。

對不斷擴張的環肽領域未來發展的演化軌跡和戰略要點的總結性觀點

總而言之，環肽處於創新化學、生物技術實力和臨床需求的交匯點。其應用範圍廣泛，涵蓋先進的治療和診斷、環境保護和研究工具，凸顯了其在生命科學中的戰略重要性。合成技術的不斷進步，加上計算設計和監管支持，正在推動該領域邁向新的發展。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 環肽合成進展提高藥物研發效率
  • 拓展環肽在癌症標靶治療和精準醫療的應用
  • 新興環肽作為對抗抗藥性病原體的新型抗菌劑
  • 創新遞送系統以提高環肽的生物有效性和穩定性
  • 加強生技公司與學術機構的合作，加速環肽研究
  • 不斷變化的監管環境影響環肽臨床試驗核准和市場准入
  • 增加對環肽類治療Start-Ups的投資和資金
  • 集診斷和治療功能於一體的多功能環肽的開發

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：按類型分類的環肽市場

  • 天然環肽
  • 合成環肽

9. 環肽市場（依產品類型）

  • 抗菌胜肽
    • Daptomycin
    • 短桿菌肽S
    • 酪胺酸
  • 荷爾蒙胜肽
    • 催產素
    • 生長抑制素
    • 加壓素
  • 免疫調節胜肽
  • 胜肽疫苗

第 10 章：環肽市場（按技術）

  • 化學合成
  • 液相合成
  • 重組DNA技術
  • 固相合成

第11章 環肽市場（依應用）

  • 農業
  • 化妝品
  • 診斷
    • 生物感測器
    • 免疫檢測
  • 研究與開發
    • 生化分析
    • 藥物研發
    • 分子生物學
  • 治療藥物
    • 心血管系統
    • 感染疾病
    • 代謝紊亂
    • 腫瘤學

第12章 環肽市場（依最終用戶）

  • 學術機構
  • 生技公司
  • 製藥公司

13. 美國環肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲環肽市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區循環胜肽市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • Kaneka Corporation
    • Bachem AG
    • TCG Lifesciences Pvt. Ltd.
    • GenScript Biotech Corporation
    • JPT Peptide Technologies GmbH
    • Thermo Fisher Scientific Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-AE420CB152AD

The Cyclic Peptides Market was valued at USD 3.16 billion in 2024 and is projected to grow to USD 3.35 billion in 2025, with a CAGR of 6.52%, reaching USD 4.61 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.16 billion
Estimated Year [2025] USD 3.35 billion
Forecast Year [2030] USD 4.61 billion
CAGR (%) 6.52%

Forging New Frontiers in Cyclic Peptide Research Through Interdisciplinary Innovation, Cross-Sector Collaboration, and Evolving Clinical Demand Dynamics

Cyclic peptides have emerged as a transformative class of therapeutic agents, distinguished by their structural rigidity, enhanced stability, and high binding affinity to challenging targets. Their unique macrocyclic framework confers resistance to proteolytic degradation, rendering them ideal candidates for applications ranging from oncology and metabolic disorders to infectious diseases and diagnostic platforms. Over the past decade, rapid advances in synthetic methodologies and biotechnological innovation have unlocked pathways to tailor cyclic peptide structures with unprecedented precision, accelerating lead identification and optimization.

Beyond therapeutic applications, cyclic peptides are increasingly leveraged in environmental protection and research domains. Their specificity and biocompatibility make them valuable tools for biochemical analysis, molecular biology, and biosensing systems. As the convergence of computational design, novel synthesis techniques, and scalable manufacturing reshapes the landscape, stakeholders across academia, biotechnology firms, and pharmaceutical companies are collaborating to harness these molecules' full potential.

Against this backdrop, the present report delivers a comprehensive exploration of industry dynamics, regulatory frameworks, and emerging regional trends. It highlights how advancements in solid-phase synthesis, hybrid technologies, and recombinant DNA methods are driving the next wave of innovation. By examining market segmentation across type, product, technology, application, and end user, decision makers will acquire a holistic view of the cyclic peptide ecosystem and its future trajectory.

Revolutionary Technological Advances and Collaborative Breakthroughs Redefining the Cyclic Peptide Research and Development Trajectory Globally

Recent years have witnessed a paradigm shift in the cyclic peptide domain, as cutting-edge technologies and strategic partnerships converge to accelerate discovery and development. Automation in synthetic platforms, coupled with enhanced purification protocols, has significantly reduced production timelines and increased yield consistency. Meanwhile, the integration of machine learning into molecular modeling has improved target engagement predictions, thereby streamlining lead optimization and mitigating late-stage failures.

Collaborations between academic institutes and industry players have further catalyzed progress. Joint ventures focused on hybrid synthesis approaches and liquid-phase methods are expanding the toolbox for peptide assembly, balancing cost-efficiency with scalability. In parallel, advancements in recombinant DNA technology enable the expression of complex cyclic structures in microbial hosts, unlocking access to novel analogs and post-translational modifications previously deemed infeasible.

On the regulatory front, agencies have introduced guidance frameworks to support peptide therapeutics, fostering expedited review pathways for candidates addressing high-unmet medical needs. This evolving ecosystem underscores the importance of adaptive R&D strategies that embrace platform flexibility, digital integration, and cross-disciplinary expertise. As the industry transitions from proof-of-concept studies to clinical translation, these transformative shifts are redefining the pace and scope of cyclic peptide innovation globally.

Analyzing the Far-Reaching Consequences of United States Tariff Adjustments in 2025 on the Cyclic Peptide Industry Ecosystem and Market Resilience

The implementation of new United States tariffs in 2025 has introduced a complex layer of strategic considerations for cyclic peptide stakeholders. Raw materials, specialized reagents, and critical intermediates sourced internationally have become subject to increased import duties, prompting a comprehensive reevaluation of sourcing strategies. Many organizations have responded by diversifying supplier bases, pursuing near-shoring options, and investing in domestic manufacturing capabilities to mitigate exposure to tariff fluctuations.

Although these adjustments have introduced upward pressure on input costs, they have simultaneously spurred innovation in process efficiency. Companies are optimizing solid-phase synthesis protocols and exploring alternative chemistries that reduce reliance on tariff-sensitive reagents. This has fostered the emergence of novel hybrid technologies and liquid-phase strategies that deliver competitive cost structures without compromising product quality.

At the same time, the heightened focus on supply chain resilience has accelerated collaborations between contract manufacturers and technology developers. By leveraging recombinant DNA platforms and modular production facilities, stakeholders are building flexible networks capable of rapid scale-up and geographic redistribution. These efforts underscore a broader industry trend: converting trade policy challenges into drivers of localized innovation and long-term stability in cyclic peptide development and manufacturing.

Unveiling Critical Segmentation Insights Illuminating Market Dynamics Across Types Methods Applications and End User Perspectives in Cyclic Peptide Domain

An in-depth examination of market segmentation reveals nuanced dynamics across multiple dimensions. In terms of structural classification, naturally derived cyclic peptides maintain strong appeal due to their inherent bioactivity and established safety profiles, while synthetic variants gain traction for their tunable properties and expanded chemical diversity. This duality drives a balanced research focus, with natural analogs often serving as blueprints for synthetic optimization.

When considering product categories, antimicrobial cyclic peptides command significant interest as potential alternatives to traditional antibiotics, with flagship compounds such as daptomycin, gramicidin S, and tyrocidine undergoing rigorous evaluation against resistant strains. Hormonal peptides, including oxytocin, somatostatin, and vasopressin, continue to underpin established therapies, even as immunomodulating peptides and innovative peptide vaccines progress through advanced discovery pipelines.

From a technological standpoint, solid-phase synthesis remains a workhorse for routine production, whereas recombinant DNA technology and hybrid approaches are unlocking access to complex cyclization patterns and post-translational modifications. Liquid-phase methods are similarly evolving, offering streamlined workflows for select chemistries. Applications across diagnostics, environmental protection, research and development, and therapeutics illustrate the versatility of cyclic peptides, with biosensors, immunoassays, biochemical analysis, drug discovery, molecular biology, cardiovascular therapies, infectious disease treatments, metabolic disorder interventions, and oncology programs each reflecting distinct development pathways.

End users span academic research centers, biotechnology firms advancing early innovation, and pharmaceutical companies focused on late-stage development and commercialization. This layered segmentation underscores the importance of targeted strategies that align platform capabilities with specific market demands and regulatory landscapes.

Evaluating Distinct Regional Dynamics Shaping Cyclic Peptide Development and Commercialization Across Americas Europe Middle East Africa and Asia Pacific Markets

Regional trends in the cyclic peptide domain vary significantly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaping distinct development and commercialization pathways. Within the Americas, robust investment in peptide innovation hubs and supportive regulatory initiatives have fostered rapid progression from bench to clinic, with many biotechnology firms establishing partnerships to expedite manufacturing scale-up.

In the Europe, Middle East & Africa region, a combination of stringent regulatory standards and collaborative consortia has driven emphasis on safety, efficacy, and harmonized approval processes. These dynamics have encouraged pharmaceutical companies to invest in cross-border alliances, leveraging local expertise in both chemical synthesis and recombinant platforms to address region-specific health challenges.

Meanwhile, Asia-Pacific has emerged as a hotspot for cost-effective manufacturing and high-throughput screening capabilities. Government-led research programs and incentives for biotechnology development have accelerated adoption of hybrid and liquid-phase synthesis methods, while contract development and manufacturing organizations expand capacity to serve global clients.

These regional insights highlight the importance of customizable strategies that account for differing regulatory regimes, reimbursement frameworks, and infrastructure maturity. By aligning R&D investments with local capabilities and policy incentives, stakeholders can optimize market entry, accelerate clinical translation, and build resilient supply chains across diverse geographies.

Profiling Key Industry Leaders Showcasing Distinct Innovative Portfolios Strategic Collaborations Propelling the Cyclic Peptide Market Forward

A focused review of leading organizations reveals diverse strategic approaches driving growth in the cyclic peptide sphere. Several pharmaceutical corporations have integrated advanced peptide platforms into their pipelines, leveraging in-house capabilities for solid-phase synthesis alongside strategic collaborations to access emerging recombinant and hybrid technologies. These alliances often center on co-development agreements, shared manufacturing networks, and joint IP portfolios that enhance speed to market.

Biotechnology firms specializing in cyclic peptides have differentiated themselves through vertical integration of discovery and process development functions. By maintaining end-to-end control over design, synthesis, and analytical characterization, these companies accelerate candidate progression while ensuring stringent quality attributes. Investments in automation and digital analytics further enable real-time process monitoring, reducing batch variability and enhancing reproducibility.

Contract development and manufacturing organizations, recognizing the complexity of cyclic peptide production, have expanded dedicated facilities and technical expertise to support both small- and large-scale projects. Their service portfolios now routinely include custom synthesis, purification, and formulation services tailored to macrocyclic structures, with expertise spanning antimicrobial compounds, hormonal analogs, and novel immunomodulators.

This competitive landscape underscores the imperative for continuous innovation in platform technologies, strategic partnerships, and capacity expansion. Organizations that harmonize scientific excellence with operational agility are best positioned to capture emerging opportunities and deliver next-generation cyclic peptide therapeutics.

Strategic Recommendations Empowering Industry Leaders to Capitalize on Emerging Opportunities and Strengthen Market Positions in Cyclic Peptide Sector

To capitalize on emerging opportunities in the cyclic peptide market, industry leaders should pursue a multipronged strategy that balances innovation, operational excellence, and market responsiveness. First, investing in platform diversification-integrating solid-phase, hybrid, and recombinant DNA technologies-will enable rapid adaptation to evolving project requirements, from simple analogs to complex macrocycles.

Second, strengthening supply chain resilience is essential. This can be achieved by establishing regional manufacturing hubs, forging partnerships with domestic suppliers to mitigate tariff exposure, and implementing advanced process controls that reduce material waste and enhance reproducibility. Collaborative networks with contract manufacturers and academic centers can further buffer against disruptions and accelerate technology transfer.

Third, aligning product portfolios with high-unmet medical needs and emerging regulatory incentives will foster smoother clinical pathways. Prioritizing antimicrobial resistance, targeted oncology applications, and novel peptide vaccines can attract expedited review mechanisms and public-private funding opportunities. Simultaneously, extending applications into diagnostics and environmental monitoring can diversify revenue streams and build long-term market resilience.

Finally, adopting digital tools-from machine learning-based design algorithms to real-time analytics in manufacturing-will optimize R&D and production workflows. By combining data-driven insights with cross-functional collaboration models, organizations can reduce development timelines, enhance quality, and sustain competitive differentiation in the cyclic peptide landscape.

Transparency in Methodological Rigor Combining Primary Research Expert Interviews and Secondary Data Synthesis to Generate Robust Insights on Cyclic Peptides

This analysis was constructed using a rigorous, multi-stage research methodology designed to ensure accuracy, relevance, and actionable insights. Initially, secondary research aggregated information from peer-reviewed publications, patent databases, regulatory filings, and authoritative industry reports. These sources provided a broad foundation of technological advancements, safety profiles, and application trends.

Subsequently, primary research involved in-depth interviews with a diverse panel of experts, including R&D leads at pharmaceutical firms, process development specialists at biotechnology companies, and regulatory consultants. These discussions illuminated practical challenges in scale-up, emerging tariff impacts, and regional regulatory nuances, yielding qualitative perspectives that enriched quantitative data.

Data synthesis employed triangulation techniques, cross-validating findings from multiple sources to minimize bias and enhance reliability. Market segmentation matrices were developed by systematically categorizing insights across structural type, product category, technology platform, application area, and end-user profile. Regional analysis incorporated economic indicators, policy frameworks, and investment trends to contextualize geographic opportunities.

Through this comprehensive approach-blending secondary intelligence with primary expert validation-the report delivers a robust framework for decision makers to navigate the dynamic cyclic peptide ecosystem with confidence.

Concluding Perspectives on the Evolutionary Trajectory and Strategic Imperatives Shaping Future Growth in the Expanding Cyclic Peptide Landscape

In summation, cyclic peptides stand at the intersection of innovative chemistry, biotechnological prowess, and clinical necessity. Their multifaceted applications-from advanced therapeutics and diagnostics to environmental protection and research tools-underscore their strategic importance across the life sciences sector. The ongoing evolution of synthesis technologies, coupled with computational design and regulatory support, is propelling the field toward new horizons.

Challenges such as supply chain disruptions and tariff adjustments have prompted the industry to embrace flexibility, driving investments in domestic manufacturing and diversified supplier networks. Simultaneously, segmentation insights reveal that tailored strategies aligned with specific product types, technological platforms, and end-user requirements are critical for sustained growth.

Regionally, adaptive approaches that reflect local regulatory environments and infrastructure capabilities will be key to unlocking market potential in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Moreover, the competitive landscape favors organizations that combine deep scientific expertise with operational agility and strategic partnerships.

Looking ahead, stakeholders that integrate data-driven decision making, platform diversification, and collaborative innovation will be best equipped to navigate complexity and seize opportunities in the expanding cyclic peptide arena. This report provides the foundational insights required to chart a path toward robust, long-term success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Advancements in cyclic peptide synthesis methods enhancing drug development efficiency
  • 5.2. Growing applications of cyclic peptides in targeted cancer therapies and precision medicine
  • 5.3. Emergence of cyclic peptides as novel antimicrobial agents against resistant pathogens
  • 5.4. Innovations in delivery systems improving cyclic peptide bioavailability and stability
  • 5.5. Rising collaborations between biotech firms and academic institutions to accelerate cyclic peptide research
  • 5.6. Regulatory landscape evolution impacting cyclic peptide clinical trial approvals and market entry
  • 5.7. Increasing investments and funding directed towards cyclic peptide-based therapeutic startups
  • 5.8. Development of multi-functional cyclic peptides combining diagnostic and therapeutic capabilities

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cyclic Peptides Market, by Type

  • 8.1. Introduction
  • 8.2. Natural Cyclic Peptide
  • 8.3. Synthetic Cyclic Peptide

9. Cyclic Peptides Market, by Product Type

  • 9.1. Introduction
  • 9.2. Antimicrobial Peptides
    • 9.2.1. Daptomycin
    • 9.2.2. Gramicidin S
    • 9.2.3. Tyrocidine
  • 9.3. Hormonal Peptides
    • 9.3.1. Oxytocin
    • 9.3.2. Somatostatin
    • 9.3.3. Vasopressin
  • 9.4. Immunomodulating Peptides
  • 9.5. Peptide Vaccines

10. Cyclic Peptides Market, by Technology

  • 10.1. Introduction
  • 10.2. Chemical Synthesis
  • 10.3. Liquid-Phase Synthesis
  • 10.4. Recombinant DNA Technology
  • 10.5. Solid-Phase Synthesis

11. Cyclic Peptides Market, by Application

  • 11.1. Introduction
  • 11.2. Agriculture
  • 11.3. Cosmetics
  • 11.4. Diagnostics
    • 11.4.1. Biosensors
    • 11.4.2. Immunoassays
  • 11.5. Research & Development
    • 11.5.1. Biochemical Analysis
    • 11.5.2. Drug Discovery
    • 11.5.3. Molecular Biology
  • 11.6. Therapeutics
    • 11.6.1. Cardiovascular
    • 11.6.2. Infectious Diseases
    • 11.6.3. Metabolic Disorders
    • 11.6.4. Oncology

12. Cyclic Peptides Market, by End User

  • 12.1. Introduction
  • 12.2. Academic Institutes
  • 12.3. Biotechnology Firms
  • 12.4. Pharmaceutical Companies

13. Americas Cyclic Peptides Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Cyclic Peptides Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Cyclic Peptides Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AstraZeneca PLC
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Kaneka Corporation
    • 16.3.4. Bachem AG
    • 16.3.5. TCG Lifesciences Pvt. Ltd.
    • 16.3.6. GenScript Biotech Corporation
    • 16.3.7. JPT Peptide Technologies GmbH
    • 16.3.8. Thermo Fisher Scientific Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. CYCLIC PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. CYCLIC PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. CYCLIC PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. CYCLIC PEPTIDES MARKET: RESEARCHAI
  • FIGURE 26. CYCLIC PEPTIDES MARKET: RESEARCHSTATISTICS
  • FIGURE 27. CYCLIC PEPTIDES MARKET: RESEARCHCONTACTS
  • FIGURE 28. CYCLIC PEPTIDES MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. CYCLIC PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CYCLIC PEPTIDES MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY NATURAL CYCLIC PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GRAMICIDIN S, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY GRAMICIDIN S, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYROCIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TYROCIDINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY OXYTOCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY OXYTOCIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOMATOSTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOMATOSTATIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY VASOPRESSIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOMODULATING PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COSMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY COSMETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY MOLECULAR BIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CYCLIC PEPTIDES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES CYCLIC PEPTIDES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 273. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 275. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 277. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 279. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. GERMANY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 281. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 285. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 287. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 288. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 289. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 291. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 293. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 295. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 296. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 297. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 299. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 301. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 307. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 309. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 311. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 313. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 314. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 315. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 317. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 319. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. RUSSIA CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 321. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. ITALY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ITALY CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. ITALY CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 327. ITALY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 328. ITALY CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 329. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. ITALY CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 331. ITALY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 332. ITALY CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 333. ITALY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 334. ITALY CYCLIC PEPTIDES MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 335. ITALY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 336. ITALY CYCLIC PEPTIDES MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2030 (USD MILLION)
  • TABLE 337. ITALY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 338. ITALY CYCLIC PEPTIDES MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 339. ITALY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 340. ITALY CYCLIC PEPTIDES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 341. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 342. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 343. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 345. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 346. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 347. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 348. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY HORMONAL PEPTIDES, 2025-2030 (USD MILLION)
  • TABLE 349. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 350. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 351. SPAIN CYCLIC PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLI